W. Marc Bernsau
Jennifer Carter is founder of N-of-One, which uses data about cancer mutations to create customized treatment plans for patients.
In the not-too-distant future, all cancer patients will have a piece of their tumor analyzed for genetic mutations and will receive a personalized readout of which specific treatment will benefit them best. And it?s likely that patients could soon describe their cancer not in terms of where it is in their body, but by the name of the mutation.
It?s a revolution that?s happening quickly, and one that has Massachusetts companies and hospitals front and center.
The first cancer drug approved to treat a specific subset of patients was Gleevec, made by Swiss drugmaker Novartis AG (NYSE: NVS).
To read more in the Boston Business Journal, click here.
the stand josh mcdaniels cotton bowl wizards of waverly place cedric benson playoff schedule charles addams
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন